Managing Risk in Hodgkin Lymphoma

James Olen Armitage, Robert W. Chen, Craig H. Moskowitz, John Sweetenham

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Approximately 90% of patients with limited-stage Hodgkin lymphoma are cured. The cure rate in advanced-stage Hodgkin lymphoma is dramatically better than it once was, but it is still lower than the rate in patients with limited disease. The choice of treatment is based on several factors, including symptoms, disease stage, extent of tumor burden, and prognosis. Positron emission tomography scanning can be used to assess the patient's stage of disease, which can allow further individualization of therapy. Traditional frontline treatment options include doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) and, for high-risk patients, bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone (BEACOPP). Autologous stem cell transplantation cures approximately 50% of patients. The antibody-drug conjugate brentuximab vedotin is very active in relapsed/refractory Hodgkin lymphoma. Data presented at the 2014 meeting of the American Society of Hematology (ASH) showed that brentuximab vedotin was beneficial in several settings, including as consolidation therapy posttransplant in patients at high risk for relapse, as first-line salvage therapy in relapsed/refractory Hodgkin lymphoma prior to autologous hematopoietic cell transplantation, and in combination with bendamustine in relapsed/refractory disease. The ASH meeting also offered promising data on novel agents, such as the programmed cell death 1 (PD-1) inhibitors. In this monograph, 4 experts in the management of Hodgkin lymphoma discuss various aspects of the disease and provide their perspectives on the new data presented at the ASH meeting.

Original languageEnglish (US)
Pages (from-to)1-19
Number of pages19
JournalClinical advances in hematology & oncology : H&O
Volume13
Issue number2
StatePublished - Feb 1 2015

Fingerprint

Hodgkin Disease
Bleomycin
Hematology
Doxorubicin
Procarbazine
Salvage Therapy
Dacarbazine
Vinblastine
Cell Transplantation
Stem Cell Transplantation
Vincristine
Etoposide
Therapeutics
Prednisone
Tumor Burden
Positron-Emission Tomography
Cyclophosphamide
Cell Death
Recurrence
Antibodies

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Armitage, J. O., Chen, R. W., Moskowitz, C. H., & Sweetenham, J. (2015). Managing Risk in Hodgkin Lymphoma. Clinical advances in hematology & oncology : H&O, 13(2), 1-19.

Managing Risk in Hodgkin Lymphoma. / Armitage, James Olen; Chen, Robert W.; Moskowitz, Craig H.; Sweetenham, John.

In: Clinical advances in hematology & oncology : H&O, Vol. 13, No. 2, 01.02.2015, p. 1-19.

Research output: Contribution to journalArticle

Armitage, JO, Chen, RW, Moskowitz, CH & Sweetenham, J 2015, 'Managing Risk in Hodgkin Lymphoma', Clinical advances in hematology & oncology : H&O, vol. 13, no. 2, pp. 1-19.
Armitage JO, Chen RW, Moskowitz CH, Sweetenham J. Managing Risk in Hodgkin Lymphoma. Clinical advances in hematology & oncology : H&O. 2015 Feb 1;13(2):1-19.
Armitage, James Olen ; Chen, Robert W. ; Moskowitz, Craig H. ; Sweetenham, John. / Managing Risk in Hodgkin Lymphoma. In: Clinical advances in hematology & oncology : H&O. 2015 ; Vol. 13, No. 2. pp. 1-19.
@article{0541ff787a244262b13579362b7fb29e,
title = "Managing Risk in Hodgkin Lymphoma",
abstract = "Approximately 90{\%} of patients with limited-stage Hodgkin lymphoma are cured. The cure rate in advanced-stage Hodgkin lymphoma is dramatically better than it once was, but it is still lower than the rate in patients with limited disease. The choice of treatment is based on several factors, including symptoms, disease stage, extent of tumor burden, and prognosis. Positron emission tomography scanning can be used to assess the patient's stage of disease, which can allow further individualization of therapy. Traditional frontline treatment options include doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) and, for high-risk patients, bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone (BEACOPP). Autologous stem cell transplantation cures approximately 50{\%} of patients. The antibody-drug conjugate brentuximab vedotin is very active in relapsed/refractory Hodgkin lymphoma. Data presented at the 2014 meeting of the American Society of Hematology (ASH) showed that brentuximab vedotin was beneficial in several settings, including as consolidation therapy posttransplant in patients at high risk for relapse, as first-line salvage therapy in relapsed/refractory Hodgkin lymphoma prior to autologous hematopoietic cell transplantation, and in combination with bendamustine in relapsed/refractory disease. The ASH meeting also offered promising data on novel agents, such as the programmed cell death 1 (PD-1) inhibitors. In this monograph, 4 experts in the management of Hodgkin lymphoma discuss various aspects of the disease and provide their perspectives on the new data presented at the ASH meeting.",
author = "Armitage, {James Olen} and Chen, {Robert W.} and Moskowitz, {Craig H.} and John Sweetenham",
year = "2015",
month = "2",
day = "1",
language = "English (US)",
volume = "13",
pages = "1--19",
journal = "Clinical Advances in Hematology and Oncology",
issn = "1543-0790",
publisher = "Millennium Medical Publishing, Inc.",
number = "2",

}

TY - JOUR

T1 - Managing Risk in Hodgkin Lymphoma

AU - Armitage, James Olen

AU - Chen, Robert W.

AU - Moskowitz, Craig H.

AU - Sweetenham, John

PY - 2015/2/1

Y1 - 2015/2/1

N2 - Approximately 90% of patients with limited-stage Hodgkin lymphoma are cured. The cure rate in advanced-stage Hodgkin lymphoma is dramatically better than it once was, but it is still lower than the rate in patients with limited disease. The choice of treatment is based on several factors, including symptoms, disease stage, extent of tumor burden, and prognosis. Positron emission tomography scanning can be used to assess the patient's stage of disease, which can allow further individualization of therapy. Traditional frontline treatment options include doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) and, for high-risk patients, bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone (BEACOPP). Autologous stem cell transplantation cures approximately 50% of patients. The antibody-drug conjugate brentuximab vedotin is very active in relapsed/refractory Hodgkin lymphoma. Data presented at the 2014 meeting of the American Society of Hematology (ASH) showed that brentuximab vedotin was beneficial in several settings, including as consolidation therapy posttransplant in patients at high risk for relapse, as first-line salvage therapy in relapsed/refractory Hodgkin lymphoma prior to autologous hematopoietic cell transplantation, and in combination with bendamustine in relapsed/refractory disease. The ASH meeting also offered promising data on novel agents, such as the programmed cell death 1 (PD-1) inhibitors. In this monograph, 4 experts in the management of Hodgkin lymphoma discuss various aspects of the disease and provide their perspectives on the new data presented at the ASH meeting.

AB - Approximately 90% of patients with limited-stage Hodgkin lymphoma are cured. The cure rate in advanced-stage Hodgkin lymphoma is dramatically better than it once was, but it is still lower than the rate in patients with limited disease. The choice of treatment is based on several factors, including symptoms, disease stage, extent of tumor burden, and prognosis. Positron emission tomography scanning can be used to assess the patient's stage of disease, which can allow further individualization of therapy. Traditional frontline treatment options include doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) and, for high-risk patients, bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone (BEACOPP). Autologous stem cell transplantation cures approximately 50% of patients. The antibody-drug conjugate brentuximab vedotin is very active in relapsed/refractory Hodgkin lymphoma. Data presented at the 2014 meeting of the American Society of Hematology (ASH) showed that brentuximab vedotin was beneficial in several settings, including as consolidation therapy posttransplant in patients at high risk for relapse, as first-line salvage therapy in relapsed/refractory Hodgkin lymphoma prior to autologous hematopoietic cell transplantation, and in combination with bendamustine in relapsed/refractory disease. The ASH meeting also offered promising data on novel agents, such as the programmed cell death 1 (PD-1) inhibitors. In this monograph, 4 experts in the management of Hodgkin lymphoma discuss various aspects of the disease and provide their perspectives on the new data presented at the ASH meeting.

UR - http://www.scopus.com/inward/record.url?scp=84979092743&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84979092743&partnerID=8YFLogxK

M3 - Article

VL - 13

SP - 1

EP - 19

JO - Clinical Advances in Hematology and Oncology

JF - Clinical Advances in Hematology and Oncology

SN - 1543-0790

IS - 2

ER -